Leonard Zehr, Author at BioTuesdays

Markets

Cantor starts Affimed at OW; PT $12

Cantor Fitzgerald initiated coverage of Affimed N.V. (NASDAQ:AFMD) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.23 on Feb. 22. Affimed, which is one of Cantor’s top picks for...

February 23, 2022

Feature

Palisade Bio guarding against post-operative disruption of GI function

Palisade Bio (NASDAQ:PALI) is advancing therapies that help patients with acute and chronic GI complications, stemming from post-operative tissue damage, to speed recovery and reduce hospital stays.

February 22, 2022

Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Feature

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Athira Pharma (NASDAQ:ATHA) is in late- and mid-stage clinical development of small molecules to restore neuronal health and slow neurodegeneration of diseases, such as Alzheimer’s, Parkinson’s and dementia.

February 8, 2022

Markets

Brookline starts Fusion Pharma at buy; PT $15

Brookline Capital Markets launched coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a “buy” rating and $15 price target. The stock closed at $7.53 on Feb. 2. Fusion is a clinical-stage oncology company focused on...

February 2, 2022

Markets

Analysts start Amylyx on strong ALS data and possible regulatory approval

Analysts for SVB Leerink and H.C. Wainwright launched coverage of Amylyx Pharmaceuticals (NASDAQ:AMLX) with “outperform” and “buy” ratings, and price targets of $50 and $35, respectively. The stock closed at $23.18 on...

February 1, 2022

Feature

Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes

Closely-held Zucara Therapeutics expects to release results in the second quarter of its Phase 1b proof-of-concept study with its once-daily drug candidate, ZT-01, to prevent insulin-induced hypoglycemia, or low blood...

February 1, 2022

Feature

Aravive developing targeted cancer therapeutics to treat metastatic disease

Aravive (NASDAQ:ARAV) is taking a differentiated approach with its lead molecule, batiraxcept, to target inhibition of the GAS6/AXL signaling pathway in several cancer indications.

January 25, 2022

Feature

POINT Biopharma creating platform for next-generation radiopharmaceuticals

POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...

January 18, 2022

Author - Leonard Zehr

Cantor starts Affimed at OW; PT $12

Palisade Bio guarding against post-operative disruption of GI function

Cantor starts vTv at OW; PT $5

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Brookline starts Fusion Pharma at buy; PT $15

Analysts start Amylyx on strong ALS data and possible regulatory approval

Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes

Aravive developing targeted cancer therapeutics to treat metastatic disease

POINT Biopharma creating platform for next-generation radiopharmaceuticals

General

More